Introduction {#sec1_1}
============

Autosomal dominant polycystic kidney disease (ADPKD), the most common genetic cause of chronic kidney disease (CKD) worldwide, results in progressive development of kidney cysts, increased kidney volume, kidney pain, hypertension, gross hematuria, and ultimately kidney failure \[[@B1]\]. In Japan, approximately 1,000 cases of end stage renal disease (ESRD) annually are attributable to ADPKD, and it is the fourth leading cause of ESRD, following diabetes, glomerulonephritis, and hypertension \[[@B2]\].

The antidiuretic hormone arginine vasopressin and its second messenger cAMP have been identified as promoters of cellular proliferation of cysts and kidney enlargement in animal models of cystic kidney disease \[[@B3]\], while vasopressin V~2~ receptor blockades have been shown to reduce cyst burden and protect kidney function in rodent models of cystic kidney disease \[[@B4]\]. As for cyst epithelial cells in humans, tolvaptan, a vasopressin V~2~ receptor antagonist, has been reported to inhibit cell proliferation and chloride-dependent fluid secretion in a dose-dependent manner \[[@B5]\]. This drug was recently introduced for treatment of ADPKD patients, following the results of the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcome (TEMPO) 3:4 trial \[[@B6]\]. The TEMPO 3:4 trial was performed as a randomized double-blind placebo-controlled parallel-group investigation, and results obtained over a 3-year period demonstrated that administration of tolvaptan reduced the annual rate of increase in total kidney volume (TKV) and lowered that of kidney function decline \[[@B6]\].

Based on the results of the TEMPO 3:4 trial, tolvaptan was initially approved by the regulatory authority in Japan in March 2014 as therapy for ADPKD patients with CKD stages 1--3, indicating rapidly progressive disease. Subsequently, the Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trial was conducted using ADPKD patients with a later CKD stage (estimated glomerular filtration rate \[eGFR\] 25--65 mL/min/1.73 m^2^) \[[@B7]\]. Results of the REPRISE trial showed a slower eGFR decline with tolvaptan as compared to a placebo. Thereafter, tolvaptan was approved by the United States Food and Drug Administration (FDA) (April 2018).

Recently, a retrospective study conducted at the Mayo Clinic in the United States showed that the effects of tolvaptan for protection of kidney function could be sustained for a long period (*n* = 97 patients, average follow-up 4.6 years) \[[@B8]\], though the effect on increasing TKV was not analyzed. Inhibition of cell proliferation and chloride-dependent fluid secretion by tolvaptan has been shown to occur in a dose-dependent manner, while its long-term efficacy and safety when given at a high dose remain unknown. Here, we present 2 Japanese ADPKD patients who received high-dose tolvaptan therapy (total daily dose 120 mg) for a period of 9 years, since the beginning of the TEMPO 3:4 trial.

Case Presentation {#sec1_2}
=================

Case 1 {#sec2_1}
------

A 36-year-old male was diagnosed with ADPKD at the Outpatient Department of our hospital in 2008, based on magnetic resonance imaging (MRI) findings. Previously in 2002, he presented with gross hematuria. Family history related to ADPKD was unclear. The patient had hypertension and was being treated with antihypertensives including valsartan (40 mg/day). Blood pressure was 108/69 mm Hg. The case was complicated with multiple liver cysts, while no other complications were noted, such as brain aneurysm or heart valve disease. An MRI examination revealed enlargement of the bilateral kidneys with multiple cysts of various sizes, and TKV determined with an ellipsoid equation was 1,497 mL. Table [1](#T1){ref-type="table"} shows blood examination and urinalysis results prior to beginning treatment with tolvaptan.

Following an explanation of the procedures, the patient explicitly expressed a desire to participate in the TEMPO 3:4 trial. eGFR, calculated using the Japanese formula \[[@B9]\], was 57.3 mL/min/1.73 m^2^, and estimated creatinine clearance calculated with the Cockcroft-Gault formula \[[@B10]\] was 78.1 mL/min (Table [1](#T1){ref-type="table"}). Thus, the patient was considered eligible to be registered. Three years after beginning the trial, when the study had finished, the clinical research coordinator of Osaka City University Hospital revealed that the patient had been assigned to the tolvaptan group. According to the protocol of the TEMPO 3:4 trial \[[@B6]\], tolvaptan was started at a dose of 60 mg/day (45 mg given in the morning, 15 mg in the evening), with a weekly increase of 30 mg/day until reaching 120 mg/day (90 mg in the morning, 30 mg in the evening).

The eGFR in this patient was 57.3 mL/min/1.73 m^2^ prior to therapy and 30.2 mL/min/1.73 m^2^ after 9 years of treatment with tolvaptan, for an annual decline of −3.01 mL/min/1.73 m^2^. Also, TKV was 1,497 mL before starting treatment and 2,328 mL after the 9-year treatment period, for an annual rate of increase of 6.2% (Fig. [1](#F1){ref-type="fig"}). TKV showed a gradual increase, from 2.4% per year during the initial 3-year period to 6.5% per year in the most recent 6-year period. After several weeks of tolvaptan treatment, the patient showed no tolvaptan-related adverse events, such as liver dysfunction, hypernatremia, or polyuria, which were common adverse events noted in the TEMPO 3:4 trial tolvaptan group \[[@B6]\]. Currently, tolvaptan treatment is continuing and his condition remains stable. During the study period, blood pressure remained stable (under 130/80 mm Hg). However, 1 year after the end of the study, it had elevated to 145/86 mm Hg and amlodipine at 2.5 mg was administrated.

Case 2 {#sec2_2}
------

A 29-year-old male with gross hematuria was diagnosed with ADPKD at the Outpatient Department of our hospital, based on MRI findings. There was a family history of ADPKD, and his father suffered from ESRD. Hypertension was also present, and the patient was being treated with antihypertensives including candesartan (8 mg/day). Blood pressure was 128/76 mm Hg. Multiple liver cysts were evident, though no other complications, including brain aneurysm or heart valve disease, were noted. The MRI examination also revealed enlargement of the bilateral kidneys with multiple cysts of various sizes, and TKV determined with an ellipsoid equation was 1,290 mL. Table [1](#T1){ref-type="table"} shows blood examination and urinalysis results prior to starting treatment with tolvaptan.

Serum creatinine was 0.97 mg/dL, the eGFR, calculated by the Japanese formula \[[@B9]\], was 76.3 mL/min/1.73 m^2^, and estimated creatinine clearance, calculated with the Cockcroft-Gault formula \[[@B10]\], was 125 mL/min (Table [1](#T1){ref-type="table"}). After obtaining informed consent, the patient was registered in the TEMPO 3:4 trial. Three years after beginning that, the clinical research coordinator of Osaka City University Hospital revealed that he had been assigned to the tolvaptan group. According to the protocol of the trial \[[@B6]\], tolvaptan was started at 60 mg/day and then increased up to 120 mg/day, the same as described above for case 1.

After 3 years of tolvaptan treatment, blood pressure showed elevation and amlodipine at 10 mg/day was added, which resulted in systolic and diastolic blood pressure values stabilizing at 132--146 and 72--86 mm Hg, respectively. At 5 years after beginning the administration of tolvaptan, blood pressure was elevated again, and the antihypertensive medication administration was changed to a combination tablet comprised of 80 mg of valsartan and 10 mg of cilnidipine, though blood pressure remained high at 150--170 mm Hg. eGFR was 76.3 mL/min/1.73 m^2^ prior to starting tolvaptan therapy and reduced to 43.5 mL/min/1.73 m^2^ after 9 years of treatment, for a decline of −3.64 mL/min/1.73 m^2^ per year. Furthermore, TKV determined with an ellipsoid equation increased from 1,290 mL before starting tolvaptan treatment to 2,570 mL at the most recent examination, for an annual rate of increase of 11.0% (Fig. [1B](#F1){ref-type="fig"}). TKV in case 2 showed a gradual increase, from 4.7% per year in the initial 3-year period to 12.5 % per year in the most recent 6-year period. Although renal cyst infection has occurred twice during the 9-year treatment period, other adverse events related to tolvaptan, such as liver dysfunction or hypernatremia, have not been seen in this patient. Currently, tolvaptan treatment is continuing and his condition remains stable.

Discussion {#sec1_3}
==========

The efficacy of tolvaptan at a daily dose of 60--120 mg for ADPKD patients has been confirmed by results of 2 different pivotal trials \[[@B6], [@B7]\]. In a subgroup analysis conducted during the 3-year TEMPO 3:4 trial, the annual eGFR change was −3.83 mL/min/1.73 m^2^ in Japanese patients \[[@B11]\]. In the present 2 cases, the annual eGFR decline during the longer 9-year observation period was −3.01 mL/min/1.73 m^2^ and −3.64 mL/min/1.73 m^2^, respectively, similar to the Japanese subgroup analysis results shown in the TEMPO3:4 trial \[[@B11]\]. Thus, high-dose tolvaptan treatment for protection of kidney function in Japanese ADPKD patients can be maintained for an extended period.

The beneficial effect of tolvaptan for ADPKD patients can be demonstrated by comparing observed (with tolvaptan treatment) and predicted (without tolvaptan treatment) eGFR values using a validated predictive equation \[[@B12]\]. Had tolvaptan treatment not been performed for the present 2 patients, eGFR after 9 years was predicted to be 14.9 mL/min/1.73 m^2^ in case 1 and 30.9 mL/min/1.73 m^2^ in case 2. With that equation, the difference between observed and predicted eGFR in case 1 was calculated to be 15.3 mL/min/1.73 m^2^, while that in case 2 was calculated to be 12.6 mL/min/1.73 m^2^. These results show the benefit of long-term tolvaptan therapy for ADPKD.

A recent retrospective study conducted at the Mayo Clinic in the United States showed that ADPKD patients treated with tolvaptan had a lower eGFR slope from the baseline (−2.20 mL/min/1.73 m^2^ per year) as compared with the control group (−3.50 mL/min/1.73 m^2^ per year) during the follow-up period (average 4.6 years) \[[@B8]\]. Although the details of each case were unclear in that study, the findings in the present patients obtained over a longer period were consistent with those of that study. Japan was the first country to approve tolvaptan for treatment of ADPKD, with more than 1,000 patients since treated, thus larger-scale and longer follow-up studies are needed to confirm the efficacy and safety of therapy for Japanese ADPKD patients.

During the 3-year TEMPO 3:4 trial, the annual rate of increase in TKV in the placebo group was 5.5%, while that in the tolvaptan group was 2.8% \[[@B6]\]. In sub-analysis findings of Japanese patients, the annual rate of increase in TKV in the placebo group was 5.0%, while that in the tolvaptan group was 1.3 % \[[@B11]\]. During the initial 3-year treatment period of the present case 1, TKV increased from 1,497 to 1,606 mL, for an annual rate of increase of 2.4%, similar to results shown in previous studies \[[@B6], [@B13]\]. Notably, TKV in case 1 showed a gradual increase over time, from 2.4% per year in the initial 3-year period to 6.5% per year during the most recent 6-year period. The increase in TKV growth in case 2 was also shown to be gradual, from 4.7% per year in the initial 3-year period to 12.5% per year in the most recent 6-year period. The effect of tolvaptan on kidney volume in the early phase of ADPKD may be due to deflation caused by reduced fluid secretion from renal cysts, while that in the late phase is thought to be related to suppressed cell proliferation \[[@B1], [@B13]\]. A recent retrospective study conducted at the Mayo Clinic in the United States did not evaluate TKV \[[@B8]\], thus this is the first case report in which evaluation of TKV over a long term was performed in ADPKD patients who received tolvaptan treatment. Considering the clinical courses of our patients, tolvaptan may be less effective when administered for more than 3--6 years, at least for inhibition of kidney volume enlargement. The exact mechanisms underlying an increase in TKV over the long term remain unknown. Studies of cases with longer follow-up periods are needed for confirmation of increased TKV.

Generally, increased TKV is associated with eGFR in ADPKD patients who do not undergo tolvaptan treatment \[[@B14]\]. That increase was not likely associated with eGFR decline in the present case 1, whereas it did seem to be at least somewhat associated with eGFR decline in case 2. Determination of TKV may not be appropriate to monitor the efficacy of tolvaptan. Indeed, a recently published review, which contains a practical guide for treatment of rapidly progressive ADPKD with tolvaptan, does not recommend annual TKV measurements to monitor efficacy of the therapy \[[@B15]\]. Further cohort studies of ADPKD patients who undergo tolvaptan treatment for a long period are needed to determine whether annual TKV measurements can predict eGFR decline and would also be informative in regard to other factors.

This is the first case report showing both long-term efficacy and safety of high-dose tolvaptan for protection of kidney function in Japanese patients with ADPKD. Results of the present 2 cases suggest that continued effectiveness with longer treatment may be reduced, at least in terms of kidney volume expansion. To confirm the effects of long-term therapy, it will be necessary to accumulate additional cases with longer periods of tolvaptan treatment.
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###### 

Laboratory examination findings prior to beginning tolvaptan treatment

  ----------------------------------------------------------
                                           Case 1   Case 2
  ---------------------------------------- -------- --------
  Age, years                               36       29

  Body mass index, kg/m^2^                 22.0     28.4

  White blood cells, µL                    4,800    6,800

  Red blood cells, µL                      487      463

  Hemoglobin, g/dL                         14.5     13.9

  Total protein, g/dL                      6.9      7.2

  Albumin, g/dL                            4.5      4.6

  Blood urea nitrogen, mg/dL               17       11

  Creatinine, mg/dL                        1.19     0.97

  Estimated glomerular filtration rate,\   57.3     76.3
  mL/min/1.73 m^2^                                  

                                                    

  Estimated creatinine clearance, mL/min   78.1     125

  Uric acid, mg/dL                         5.5      7.4

  Aspartate transaminase, IU/L             21       28

  Alanine transaminase, IU/L               21       29

  Sodium, mEq/L                            145      143

  Potassium, mEq/L                         4.1      4.2

  Chloride, mEq/L                          105      106

  Urinary protein                          (±)      (−)

  Urinary occult blood                     (−)      (−)
  ----------------------------------------------------------
